An Open Label Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MEK162 in Noonan Syndrome Hypertrophic Cardiomyopathy

Trial Profile

An Open Label Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MEK162 in Noonan Syndrome Hypertrophic Cardiomyopathy

Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 28 Jan 2016

At a glance

  • Drugs Binimetinib (Primary)
  • Indications Hypertrophic cardiomyopathy
  • Focus Therapeutic Use
  • Sponsors Novartis
  • Most Recent Events

    • 28 Dec 2015 Status changed from recruiting to withdrawn prior to enrolment as reported by ClinicalTrials.gov record.
    • 20 Oct 2014 Planned End Date changed from 1 Mar 2017 to 1 May 2017 according to ClinicalTrials.gov rcord.
    • 20 Oct 2014 Planned primary completion date changed from 1 Mar 2017 to 1 May 2017 according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top